Precipio, Inc. Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pennsylvania
January 22, 2018 at 08:27 am EST
Share
Precipio, Inc. announced it is collaborating with the cytogenetics laboratory at the University of Pennsylvania to conduct an external validation and evaluation of IV-Cell, Precipio's cytogenetics media. Validation by an external laboratory represents the first step in bringing this product to market. The completion of this study is expected to provide strong, independent evidence of its performance, and will serve as an important tool during discussions with the leading manufacturers to acquire this technology. The study will be conducted over a period of approximately six to eight weeks and will include the testing of over 50 clinical specimens. During the study, the Penn team will do a side-by-side comparison between their current culture media, and Precipio's media. The study will evaluate two key elements of Precipio's media. First, its ability to enable laboratory technicians to culture multiple cell lineages simultaneously compared to their existing media that requires the laboratory to select up-front the target cell lineage; once that cell lineage is selected, it cannot be changed. The ability to culture multiple cell lineages using IV-Cell represents a significant advantage that can provide the laboratory with a more complete picture of the patient specimen, and can ultimately lead to a more accurate diagnosis. The second advantage, is a significantly higher resolution of the chromosomal bands that are created during the process. This increases the cytogeneticists' ability to correctly identify any abnormalities that may be present, resulting in a more accurate diagnosis.
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.